KEYTRUDA Inf Konz 100 mg/4ml Durchstf

Keytruda, Konzentrat zur Herstellung einer Infusionslösung

Quelle				
Compendium	Keytruda Inf Konz 100 mg/4ml	compendium.ch®		
SAI	KEYTRUDA Inf Konz 100 mg/4ml Durchstf	rof 1:12		

Medicinal Product						
MPID	CH-7601	001001138-6623101	Medicinal Product			
Approved Dose Form (EXT)	KOINF	Konzentrat zur Herstellung einer Infusionslösung	MPID: II Combined Pharmaceutical Dose Forn Additional Monitoring Indicator: CD [0. Special Measures: ST [0*] Paediatric Use Indicator: CD [01] Orphan Designation Status: CD [01]	.1] _		

Product Classification			
ATC (Code System)	L01FF02	Product Classification	
Heilmittelcode (Value)	BT – Biotechnologika	- Code System: CD.codeSystem - Value: CD.code	

Medicinal Produ	uct Name			
Type (EXT)	Original			
Full Name	KEYTRU	JDA Inf Konz 100 mg/4ml Durchstf		- Full Name: ST
Invented Name Part	KEYTRUDA			Invented Name Part: ENXP [0*] Scientific Name Part: ENXP [0*] Strength Part: ENXP [0*] Pharmaceutical Dose Form Part: ENXP [0*] Formulation Part: ENXP [0*]
Strength Part	100 mg/-	4ml		Intended Use Part: ENXP [0*] Target Population Part: ENXP [0*]
Pharmaceutical Dose Form Part	Inf Konz			Container or Pack Part: ENXP [0*] Device Part: ENXP [0*] Trademark or Company Name Part: ENXP [0*] Time / Period Part: ENXP [0*] Flavour Part: ENXP [0*] Delimiter Part: ENXP [0*]
Container or Pack Part	Durchstf			- 1
Country / Langu	ıage			
Language	de	Deutsch		Country / Language - Country: CD - Jurisdiction: CD [01] - Language: CD

Medicinal Produ	ıct Name			
Type (EXT)	BAG		Medicinal Product Name - Full Name: ST	
Full Name	KEYTRU	JDA Inf Konz 100 mg/4ml	- Invented Name Part: ENXP [0*] - Scientific Name Part: ENXP [0*]	
Invented Name Part	KEYTRU	JDA	- Strength Part: ENXP [0*] - Pharmaceutical Dose Form Part: ENXP [0*] - Formulation Part: ENXP [0*] - Intended Use Part: ENXP [0*] - Target Population Part: ENXP [0*]	
Strength Part	100 mg/4	4ml	- Container or Pack Part: ENXP [0*] - Device Part: ENXP [0*]	
Pharmaceutical Dose Form Part	Inf Konz		- Trademark or Company Name Part: ENXP [0*] - Time / Period Part: ENXP [0*] - Flavour Part: ENXP [0*] - Delimiter Part: ENXP [0*]	
Country / Langu	ıage			
Language	de	Deutsch	Country / Language - Country: CD - Jurisdiction: CD [01] - Language: CD	

Marketing Auth	orisation	(Medicinal Product)		
Marketing Authorisation Type (EXT)	tbd			Marketing Authorisation
Marketing Authorisation Number	662310	1	1	Marketing Authorisation Number: II Country: CD [1*] Legal Status of Supply: CD Authorisation Status: CD Authorisation Status Date: TS Validity Period Start: TS
Legal Status of Supply	A	Einmalige Abgabe auf ärztliche oder tierärztliche Verschreibung (A)		Validity Period End: TS Data Exclusivity Start Date: TS [01 Data Exclusivity End Date: TS [01] Date of First Authorisation: TS [01]
Authorisation Status	Z	Zugelassen		International Birth Date: TS
Authorisation Status Date	22.02.2	017	- MPID: II - Combined Pharr - Additional Monito	maceutical Dose Form: CD [01] oring Indicator: CD [01]
Validity Period End	31.12.9	999		es: ST [0*] ndicator: CD [01] tion Status: CD [01]
Date of First Authorisation	22.02.2	017		

Marketing Authorisation Holder (Organisation)				
Name	MSD Merck Sharp & Dohme AG	Marketing Authorisation Holder (Organisation)		
GLN	7601001001138			

Hinweis: Pack Size, 1 Durchstechflasche.					
Packaged Medicinal Product					
PCID	CH-7601001001138-6623101-001				
Package Description	KEYTRUDA Inf Konz 100 mg/4ml Durchstf	- PCID: II - Package Description: ST			
Pack Size (EXT)	1 Durchstechflasche(n)				

Data Carrier Id	entifier			
GTIN (Code System)	7680662310018			Data Carrier Identifier - Code System: CD.codeSystem - Value: CD.code
Packaged Item	(Container)			
Package Item (Container) Type	30009000		Вох	Package Item (Container) - Package Item (Container) Type: CD
Package Item (Container) Quantity	1			- Package Item (Container) Quantity: PQ - Material: CD [1*] - Alternate Material: CD [0*]
Material	Karton			
Packaged Item	(Container)			
Package Item (Container) Type	30069000		Vial	Package Item (Container) - Package Item (Container) Type: CD
Package Item (Container) Quantity	1			- Package Item (Container) Quantity: PQ - Material: CD [1*] - Alternate Material: CD [0*]
Material	Glas			
Package (Com	ponent)			
Component Type	30064000	Stopp	per	Package (Component)
Component	200000003200 Alum		nium,	- Component Type: CD - Component Material: CD [0*]
Material	20000000322	26 Rubb	er	- Component Alternate Material: CD [0*]
Packaged Item	(Manufacture	d Item)		
Manufactured Item Quantity	4 r	ml		Manufactured Item - Manufactured Dose Form: CD - Unit of Presentation: CD [01] - Manufactured Item Quantity: PQ
Marketing Auth	norisation (Pag	ckaged M	edicinal Product)	
Marketing Authorisation Number	66231001			Marketing Authorisation - Marketing Authorisation Number: II - Country: CD [1*]
Legal Status of Supply	A Einmalige Abgabe auf ärztliche oder tierärztliche Verschreibung (A)			- Legal Status of Supply: CD - Authorisation Status: CD - Authorisation Status Date: TS - Validity Period Start: TS - Validity Period End: TS - Data Exclusivity Start Date: TS [01]
Authorisation Status	Z Zugelassen 22.02.2017			Data Exclusivity End Date: TS [01] Date of First Authorisation: TS [01] International Birth Date: TS
Authorisation Status Date				Packaged Medicinal Product - PCID: II - Package Description: ST

Shelf Life / Storag	ge		
Shelf Life Type	100000073403	Closed package	
Shelf Life Time Period	tbd		
Special Precautions of Storage	2	Im Kühlschrank (2°C – 8°C)	Shelf Life / Storage
	L	vor Licht Schützen	- Shelf Life Type: CD - Shelf Life Time Period: PQ
	NF	Nicht einfrieren	- Special Precautions for Storage: CD [0*]
	Bei Swissmedic angefragt	Nicht schütteln	
	OVP	In der Originalverpackung aufbewahren.	

Manufactured Item				
Manufactured Dose Form	11210000	Solution for infusion	Manufactured Item - Manufactured Dose Form: CD	
Unit of Presentation	15060000	Vial	- Unit of Presentation: CD [01] - Manufactured Item Quantity: PQ	

Ingredient (Manufactured Item) / Substance / Strength / Reference Strength						
Ingredient Role	WIRKS	Wirkstoff	Ingredient Ingredient Role: CD Altergenic Indicator: BL [01]			
Substance	DPT0O3T46P	Pembrolizumabum	Specified Substance - Secolfied Substance: CD			
Strength (presentation)	100 mg (per UoP)		- Substance: CD - Specific	ed Substance Group; CD entialty Indicator; CD [01]		
,	(per our)		Strength (Presentation): RTO-PQ,PQ> Strength (Concentration): RTO-PQ,PQ> [0,1] - Measurement Point: ST [0,1] - Country: CD [0,1]	Reference Stehagh Reference Substance: CD [0.1] Reference Specified Substance: CD [0.1] Reference Specified Substance: CD [0.1] Reference Stength Resurement Point: ST [0.1] Reference Stength Measurement Point: ST [0.1]		

Ingredient (Ma	Ingredient (Manufactured Item) / Substance / Strength / Reference Strength				
Ingredient Role	HNIDK	Hilfsstoff	Ingredient Ingredient Role: CD Altergenio Indicator: BL [01]		
Substance	4QD397987E	Histidinum	Substance Specified Substance - Secified Substance CD		
		Histidini hydrochloridum monohydricum	- Substance: CD - Speci	Reference Strength	
	6OZP39ZG8H	Polysorbatum 80	- Measurement Point: ST [0.1] - Reference Strength: RTO <pq.pq></pq.pq>	Reference Specified Substance: CD [0,,1] Reference Strength: RTO <pq.pq></pq.pq>	
	FST467XS7D	Saccharum	- Country: CD [0*]	Reference Strength Measurement Point: ST [01] Reference Strength Country: CD [01]	
	059QF0KO0R	Aqua ad iniectabile			

Pharmaceutica	I Product / Route	of Administration	
Administrable Dose Form	11210000	Solution for infusion	Pharmaceutical Product
Unit of Presentation	15060000	Vial	- Administrable Dose Form: CD - Unit of Presentation: CD [01]
Route of Administration	20045000	Intravenous use	
Methode of Administration (Swissmedic)	20000002043	Infusion	Route of Administration - Route of Administration: CD

Therapeutic Indication			
Indication as	10027400	Melanom	Therapeutic Indication
Intended Effect	20000003194	Therapy	Indication Text: ST Indication as "Disease / Symptom / Procedure": CD [01] Disease Status: CD [01] Comorbidity: CD [01] Intended Effect: CD [01] Timing / Duration: PQ [01]

Therapeutic Indication			
Indication as	10028881	Nicht-kleinzelliges Lungenkarzinom	Therapeutic Indication - Indication Text: ST
Intended Effect	20000003194	Therapy	Indication as "Disease / Symptom / Procedure": CD [01] Disease Status: CD [01] Comorbidity: CD [01] Intended Effect: CD [01] Timing / Duration: PQ [01]

Therapeutic Indication			
Indication as	10021782	Kopf- und Halskarzinom	Therapeutic Indication
Intended Effect	20000003194	Therapy	Indication Text: ST Indication as "Disease / Symptom / Procedure": CD [01] Disease Status: CD [01] Comorbidity: CD [01] Intended Effect: CD [01] Timing / Duration: PQ [01]

Therapeutic Indication			
Indication as	10019927	Klassisches Hodgkin Lymphom	Therapeutic Indication - Indication Text: ST
Intended Effect	20000003194	Therapy	- Indication text. S1 - Indication as "Disease / Symptom / Procedure": CD [01] - Disease Status: CD [01] - Comorbidity: CD [01] - Intended Effect: CD [01] - Timing / Duration: PQ [01]

Therapeutic Indication					
Indication as	10043971	Primäres mediastinales grosszelliges B-Zell-			Therapeutic Indication
		Lymphom			Indication Text: ST Indication as "Disease / Symptom / Procedure": CD [01]
Intended Effect	200000003194	Therapy		- (Disease Status: CD [01] Comorbidity: CD [01] Intended Effect: CD [01] Timing / Duration: PQ [01]